SCHEMBL1938587

SCHEMBL1938587

COC1=CC(O)=CC(O)C1C=CC(=O)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
BCHE P06276 3/20 0.41
MAPT P10636 3/20 0.41
CYP3A4 P08684 2/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
LMNA P02545 1/20 0.41
AKT1 P31749 2/20 0.40
GAA P10253 1/20 0.39
PKM P14618 1/20 0.39
MAOB P27338 3/20 0.38
ALDH1A1 P00352 2/20 0.38
TNFRSF1A P19438 2/20 0.38
MEN1 O00255 1/20 0.38
HSPD1 P10809 1/20 0.38
HSPE1 P61604 1/20 0.38
KMT2A Q03164 1/20 0.38
CYP1B1 Q16678 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11872634 0.82 MAPT (0.40) NPC1RAB9ABCHEMAPTCYP3A4
SCHEMBL28015499 0.80 NPC1 (0.41) NPC1RAB9ABCHEMAPTCYP3A4
SCHEMBL31237584 0.76 F3 (0.46) NPC1RAB9AMAPTLMNAMAOB
SCHEMBL6253962 0.71 DPP4 (0.46) MAPTLMNAALDH1A1
SCHEMBL28079142 0.69 MAPT (0.40) NPC1RAB9ABCHEMAPTCYP3A4
SCHEMBL6364833 0.68 MAPT (0.44) NPC1RAB9ABCHEMAPTCYP3A4
SCHEMBL27641444 0.65 NPC1 (0.37) NPC1RAB9ABCHEMAPTCYP3A4
SCHEMBL27741901 0.63 NPC1 (0.40) NPC1RAB9ABCHEMAPTCYP3A4
SCHEMBL11073619 0.62 MAPT (0.70) NPC1RAB9ABCHEMAPTCYP3A4
SCHEMBL2954324 0.62 MAPT (0.70) NPC1RAB9ABCHEMAPTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9061984-B2 Compounds related to chalcones and benzothienopyrimidines, their synthesis, and uses to treat diseases UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2015-06-23 US disclosed
US-20110190325-A1 COMPOUNDS, THEIR SYNTHESES, AND THIER USES THE JOHNS HOPKINS UNIVERSITY 2011-08-04 US disclosed
EP-2330906-A1 COMPOUNDS, THEIR SYNTHESES, AND THEIR USES University Of Louisville Research Foundation, Inc. (US) 2011-06-15 EP disclosed
WO-2010019861-A1 COMPOUNDS, THEIR SYNTHESES, AND THEIR USES UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2010-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190325-A1 COMPOUNDS, THEIR SYNTHESES, AND THIER USES TERT, TYMS, NISCH NPC1 1044/4885RAB9A 3037/4885BCHE 1009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.